Introduction
Chronic low back pain (CLBP) is a challenging condition that affects a significant percentage of the adult population worldwide every year and contributes to disability and social isolation. Invasive procedures such as facet joint injections are used to treat CLBP when alternative pain management therapy fails. The use of epidural steroid injections (ESIs) for CLBP and other radicular pain-related conditions has become standard practice in interventional pain management. The efficacy of ESIs, however, remains controversial, as the cost effectiveness and realistic expectations of pain relief are difficult to quantify 1 . According to Chon and Moon, evidence regarding the safety of ESI administration and its positive effects is lacking, although the procedure has a low incidence of complications 2 . Delivering corticosteroids into the epidural space in theory reduces pain because of the anti-inflammatory and immune-modulating properties of steroids 3 . Because they inhibit prostaglandin synthesis, block phospholipase A2, and stabilize inflammatory cell membranes, corticosteroids have a significant antiinflammatory effect 4 . 
Discussion
The elevation of IOP >20 mmHg is known to cause acute glaucoma, blurring vision, and even subjective visual loss with or without nonpositional headache 7 .
Steroid-induced transient glaucoma caused by systemic use of steroids is widely reported in the literature, yet raised IOP induced by administration of ESIs is rarely documented. Because the actual pathophysiologic mechanism is unclear, clinical anesthesiologists must be aware of the possibility of acute visual loss in patients, especially among those with predisposing risk factors, such as family history and preexisting ophthalmic conditions, prior to administering ESIs. Accurate assessment and diagnosis are necessary to ensure patient safety and to manage acute vision loss appropriately and promptly when transient glaucoma occurs. The incidence of ocular side effects is not well documented in the literature, suggesting that ocular side effects are rare or unrecognized in association with ESIs. An elevation of IOP is usually painless and occurs because aqueous outflow is blocked by the peripheral iris. The regulation of IOP occurs through balancing the fluid secretion and drainage of aqueous humor via the uveoscleral outflow pathway 11 . Steroid-induced IOP elevation may contribute to increased resistance to aqueous flow within the trabecular meshwork where approximately 90% of aqueous humor is drained from the eye 12 . When the anterior chamber angle is occluded, risk of permanent vision loss from ocular ischemia is possible as the IOP pressure increases rapidly 13 . Steroidinduced glaucoma was first described in the 1950s with the administration of systemic steroids 14 . Patients in a high steroid responders group, around 5% of the population, are more likely to encounter iatrogenic hypertension or transient glaucoma regardless of the route of steroid administration, yet the symptoms can be relatively limited until the patient notices visual disturbances 15 . 
Conclusion
Clinical anesthesiologists Orthopaedics specialists must perform comprehensive pre procedural assessments, including routine eye tests and IOP measurement, in patients scheduled for an ESI. Identifying causative factors, such as predisposing medical conditions and family history that may contribute to developing transient glaucoma, might better predict and identify patients at risk for steroid induced ophthalmic complications. Clinicians should inform patients about the potential for visual complications associated with pain procedures involving steroids, and patients with predisposing factors who have received ESIs should have a routine eye examination within 3 weeks as part of their follow-up care. Among high-risk groups, alternative pain management therapies should be considered if possible.
